How Long Can You Live With Prostate Cancer Without Treatment?

Reading Time: 7 minutes

Medically Approved by Dr Aqua Asif (15/3/25) and Mr Alan Doherty GMC: 3279241 (24/3/2026)

At a Glance

Many men diagnosed with prostate cancer — especially early-stage disease — live for years and often die of unrelated causes. Five-year survival for stage 1–2 prostate cancer is almost 100%, and even stage 3 carries around 95% survival. Prognosis depends on stage, Gleason grade, age, and overall health, making an individual assessment with a urologist essential.

Stage matters most – localised prostate cancer (stages 1–2) has near-100% five-year survival; stage 4 drops to around 50%
Not all cancers need immediate treatment – low-risk disease can be safely monitored with active surveillance under specialist guidance
Treatment options are improving – focal therapies like HIFU (NICE IPG424) and NanoKnife- IRE (NICE IPG768) target the tumour while preserving quality of life
Individual assessment is essential – PSA level, Gleason score, MRI findings, and your overall health all shape the right path forward

Many men diagnosed with prostate cancer live for years — and often die of something else entirely. Five-year survival for localised prostate cancer (stages 1–3) exceeds 95% in England (Cancer Research UK).

Life expectancy depends on several factors: how advanced the cancer is when found , the prostate cancer stage, how quickly it is likely to grow, the prostate cancer grade, grade, the man’s age and overall health, his ethnic background, and the treatment he receives. It is important to remember that life expectancy figures are averages based on large groups — they cannot predict exactly what will happen to any one individual.

What does prostate cancer prognosis mean?

Prostate cancer prognosis is generally favourable — five-year survival exceeds 95% for localised disease (stages 1–3) according to Cancer Research UK data. NICE guideline NG131 recommends that clinicians discuss prognosis with patients based on their individual risk profile, including stage, Gleason Grade Group, and PSA level.

Prognosis considers how advanced the cancer is, how aggressive it appears under the microscope (the Gleason Grade Group), and various aspects of a patient’s health and medical history. It is not a precise prediction for any one individual — rather, it provides general expectations based on statistical averages. In our clinic’s experience of over 2,000 procedures, men with localised disease treated with focal therapy maintain excellent quality of life, with 90%+ preserving sexual function and 97% maintaining urinary continence (FTC audit, n=265)

How common is prostate cancer?

Prostate cancer is the most frequently diagnosed malignancy in men in the United Kingdom – approximately one in eight men will be diagnosed with it at some stage in their lifetime. At the Focal Therapy Clinic we see men of all age groups and risk profiles. Several factors affect prevalence rates:

Age: Risk rises with age, and most diagnoses occur in men over 50.
Ethnicity: Men of African or African-Caribbean heritage have a higher risk compared to other groups.
Family history: Having a close male relative who has or had prostate cancer, or a close female relative with a history of breast cancer can significantly increase your own risk. (See our guide here)

How quickly does prostate cancer spread?

Most prostate cancers grow slowly — many low-grade tumours (Gleason 6, Grade Group 1) take years or even decades to progress and may never need treatment. NICE guideline NG131 recommends active surveillance rather than immediate intervention for these low-risk cases.

The Gleason score (or Grade Group) is a key indicator of aggressiveness: Grade Group 1 (Gleason 6) is low-risk, while Grade Groups 4–5 (Gleason 8–10) indicate faster-growing disease. The stage at diagnosis shows how far it has spread — localised cancer is confined to the prostate, while advanced cancer has reached lymph nodes, bones, or other organs. A quickly rising PSA level may suggest more aggressive disease, but PSA alone is not enough to tell the whole story. For detailed information about where prostate cancer typically spreads, see our guide on prostate cancer metastasis and spread patterns.

Why are people scared to get treatment?

Many men worry about prostate cancer treatment, mainly because of the potential for side effects like urinary incontinence and erectile dysfunction. These concerns are valid: traditional whole-gland treatments such as radical prostatectomy and radiotherapy do carry meaningful side-effect risks.

However treatment techniques and options are improving especially for localised prostate cancer: Active Surveillance avoids any treatment risk for early stage disease and Focal Therapy targets only the cancerous tissue while preserving healthy prostate. In our clinic’s experience, focal therapy preserves sexual function in 90%+ of men and urinary continence in 97% (FTC audit, n=265). Most patients return to normal activities within two weeks.

“The fear of side effects is one of the main reasons men delay treatment — but with focal therapy, we can treat the cancer while protecting quality of life. It is important to discuss all options with a specialist before making a decision.”

Mr Raj Nigam, Consultant Urological Surgeon,

It is really important to have an open and honest conversation with your urologist about any fears you have — understanding all your options, including focal therapy, can help you make an informed decision.

How is prostate cancer treated?

Treatment options vary based on the stage and risk category of the cancer. NICE guideline NG131 recommends that treatment decisions are made by a multidisciplinary team (MDT) based on your individual diagnosis:

Treatment	Description
Active Surveillance	Monitoring low-risk prostate cancer without immediate treatment. Involves regular PSA tests, DREs, and possibly repeat biopsies and MRI scans. Recommended by NICE NG131 for low-risk disease.
Surgery (Radical Prostatectomy)	Removal of the prostate gland and surrounding tissues. Often recommended for localised cancer. Carries risks of urinary incontinence and erectile dysfunction.
Radiotherapy	Uses high-energy rays to kill cancer cells. Can be given externally (external beam radiotherapy) or internally (brachytherapy, where radioactive seeds are implanted in the prostate).
HIFU (High-Intensity Focused Ultrasound)	A non-invasive treatment that uses focused ultrasound waves to heat and destroy cancer cells within the prostate, while aiming to preserve surrounding healthy tissue. In our clinic’s experience, 90%+ of men preserve sexual function and 97% maintain urinary continence (FTC audit, n=265).
NanoKnife (IRE Therapy)	Uses electrical pulses to destroy cancer cells, with the aim of minimising damage to surrounding nerves and tissues. Particularly effective for tumours near critical structures such as the urethra or neurovascular bundles.
Hormone Therapy	Reduces testosterone levels to slow cancer growth. Often used for more advanced cancers or in combination with radiotherapy.
Chemotherapy	Used for advanced or metastatic prostate cancer.

Explore: Symptoms, Treatment Options, HIFU

Prostate cancer survival rates

Survival rates are often described as “5-year survival rates,” which show the percentage of men who are still alive five years after diagnosis (Cancer research UK) . It is important to remember that these are averages based on large groups of people. They cannot predict exactly what will happen in your own case. Also, these figures usually come from data collected several years ago, and treatments are constantly improving. The figures below are net survival statistics for men diagnosed between 2013 and 2017.

For men with localised disease who choose Focal Therapy The Focal Therapy Clinic’s audit data shows 90% remain cancer-free at one year (FTC audit, n=265), with 90%+ preserving sexual function and 97% maintaining urinary continence.

5-Year Survival Rates by Stage

The following survival statistics are for men diagnosed with prostate cancer in England between 2013 and 2017.

Stage	Description	5-Year Survival Rate (2013-2017)
Stage 1	The cancer is in only half of one side of the prostate, or less. It’s completely contained within the prostate gland.	Almost 100%
Stage 2	The cancer is in more than half of one side of the prostate, but it’s still completely contained within the prostate gland.	Almost 100%
Stage 3	The cancer has broken through the covering (capsule) of the prostate. It may have spread into the tubes that carry semen (seminal vesicles).	Around 95%
Stage 4	The cancer has spread to nearby organs (like the bladder or rectum), nearby lymph nodes, or to other parts of the body outside the pelvis.	Around 50%

Stage 3 Prostate Cancer Symptoms and Prognosis

Stage 3 prostate cancer (also called locally advanced prostate cancer ) occurs when the cancer has spread just betond the prostate capsule but hasn’t reached distant organs or lymph nodes. At this stage, the tumour may grow into nearby tissues such as the seminal vesicles or bladder neck.

If you are experiencing symptoms and want to understand what they might mean, see our complete guide to early prostate cancer symptoms.

Stage 3 Prostate Cancer Prognosis / Survival rates

The prognosis for stage 3 prostate cancer is generally favourable compared to more advanced stages. According to Cancer Research UK, the five year survival rate for locally advanced prostate cancer is around 95%, with many men can living well beyond this timeframe. NICE guideline NG131 recommends that treatment for locally advanced disease is discussed within a multidisciplinary team.

Several factors influence individual prognosis:

Gleason score: Lower scores (6-7) typically indicate slower-growing cancer with better outcomes.
PSA levels: Lower PSA levels at diagnosis are generally associated with better prognosis.
Extent of local spread: Whether cancer had reached the seminal vesicles or other nearby structures.
Response to treatment: How effectively the cancer responds to initial therapy.
Overall health: General fitness and any other medical conditions

Stage 3 Prostate Cancer Treatment Options

Stage 3 prostate cancer is typically treated with a combination of approaches. Common treatment pathways include:

Radical prostatectomy: Surgical removal of the prostate gland, often combined with lymph node removal.
External beam radiotherapy: High energy radiation targeted at the prostate and surrounding areas.
Hormone therapy (ADT): Often used alongside radiotherapy to improve outcomes.
Focal therapy: In carefully selected cases, targeted treatment like HIFU or NanoKnife may be appropriate for localised tumours within stage 3 disease.

Treatment decision should be made in consultation with a Multidisciplinary team, taking into account your specific diagnosis, overall health, and personal preferences. If you have been diagnosed with Stage 3 Prostate Cancer and would like to explore your treatment options the multidisciplinary team at the Focal Therapy Clinic can provide you with a balanced comprehensive assessment.

Get Expert Advice & The Latest Research

Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.

Frequently Asked Questions

How long can one live with stage 4 prostate cancer?

There is no single answer, as everyone’s experience is different. Some men live for many years with effective treatment, while others have a more aggressive form of the disease. Five-year survival for stage 4 prostate cancer is around 50% (Cancer Research UK), but outcomes vary widely depending on where the cancer has spread and how it responds to treatment. Treatment is constantly improving — newer therapies including hormone therapy, chemotherapy, and targeted treatments are helping men with metastatic prostate cancer live longer. Discuss your individual prognosis with a consultant urological surgeon who can assess your specific case.

What happens if prostate cancer is left untreated?

The outcome depends on how aggressive the cancer is. Low-risk prostate cancers (Gleason 6, Grade Group 1) may remain indolent for years without causing harm — NICE guideline NG131 recommends Active Surveillance for these cases rather than immediate treatment. Higher-risk cancers (Grade Groups 4–5) can spread to bones and lymph nodes, eventually becoming life-threatening. A proper diagnosis — including PSA, Gleason score/Grade Group, and MRI — is essential. Discuss your individual case with a consultant urological surgeon.

How long does it take prostate cancer to develop?

Prostate cancer often develops slowly, over many years. Some low-risk cancers (Gleason 6, Grade Group 1) may stay slow-growing for decades and never need treatment. More aggressive forms (Gleason 8–10, Grade Groups 4–5) can develop and spread more quickly. Regular screening with PSA tests can help spot changes early, and MRI-guided assessment can identify cancers that need intervention.

What is the general prognosis of prostate cancer?

Prostate cancer generally carries a better prognosis compared to many other cancer types because it is often slow-growing and effective treatments are available. Five-year survival for localised prostate cancer (stages 1–3) exceeds 95% in England (Cancer Research UK). For men with localised disease, options include active surveillance, surgery, radiotherapy, and focal therapies like HIFU (NICE IPG424) and NanoKnife IRE (NICE IPG768), which offer excellent outcomes while preserving quality of life.

Patients can also explore patient stories to learn about real experiences with different treatment approaches and better understand the care pathway.